

Cite this: *Chem. Sci.*, 2023, 14, 10962

All publication charges for this article have been paid for by the Royal Society of Chemistry

Post-synthetic benzylation of the mRNA 5' cap via enzymatic cascade reactions†

N. V. Cornelissen,[‡] R. Mineikaitė,[‡] M. Erguven,^{ab} N. Muthmann,^a A. Peters,^a A. Bartels^a and A. Rentmeister^{ab}

mRNAs are emerging modalities for vaccination and protein replacement therapy. Increasing the amount of protein produced by stabilizing the transcript or enhancing translation without eliciting a strong immune response are major steps towards overcoming the present limitations and improving their therapeutic potential. The 5' cap is a hallmark of mRNAs and non-natural modifications can alter the properties of the entire transcript selectively. Here, we developed a versatile enzymatic cascade for regioselective benzylation of various biomolecules and applied it for post-synthetic modification of mRNA at the 5' cap to demonstrate its potential. Starting from six synthetic methionine analogues bearing (hetero-)benzyl groups, S-adenosyl-L-methionine analogues are formed and utilized for N7G-cap modification of mRNAs. This post-synthetic enzymatic modification exclusively modifies mRNAs at the terminal N7G, producing mRNAs with functional 5' caps. It avoids the wrong orientation of the 5' cap—a problem in common co-transcriptional capping. In the case of the 4-chlorobenzyl group, protein production was increased to 139% during *in vitro* translation and to 128–150% in four different cell lines. This 5' cap modification did not activate cytosolic pathogen recognition receptors TLR3, TLR7 or TLR8 significantly more than control mRNAs, underlining its potential to contribute to the development of future mRNA therapeutics.

Received 25th July 2023
Accepted 28th August 2023

DOI: 10.1039/d3sc03822j

rsc.li/chemical-science

Introduction

The past few years have witnessed a massive surge in the interest and use of mRNA for medical applications. In particular, the rapid development of mRNA-based vaccines against the SARS-CoV-2 coronavirus has not only boosted technology development and large-scale production, but also set the stage for approval of this therapeutic modality. In addition to its numerous applications as vaccine against infectious diseases¹ or personalized cancer treatment,² mRNA has potential for protein replacement therapy.³ However, this application will require repeated and much higher doses and the immune response to mRNA has to be restrained.⁴ A key challenge in the development of mRNA-based therapeutics is therefore to increase the amount of protein produced as well as the timespan of protein production without eliciting an overshooting immune response. To this end, a variety of modifications at the 5' cap, the entire

sequence and the poly(A) tail have been tested and shown to provide improvements.⁵

The 5' cap stabilizes eukaryotic mRNAs and is crucial for translation and reduced immune response compared to uncapped RNA.⁶ Within the >1000 nt long transcripts, it is a privileged structure, as even small modifications at the 5' cap provide a powerful lever to modulate stability, translation, and immunogenicity.^{5b,7}

To make mRNA with a 5' cap, *in vitro* transcription (IVT) in the presence of a synthetic 5' cap analogue which leads to a cap 0 (m⁷GpppG) or cap 1 (m⁷GpppAm) structure is most widely used. An anti-reverse cap analogue (7-methyl(3'-O-methyl)GpppG termed ARCA) is used to avoid wrong cap incorporation that would lead to translationally silent mRNA.⁸ Accordingly, to test modifications at the 5' cap, the respective analogues can simply be introduced to the IVT.^{7c,d}

However, despite the need to assess how altered 5' caps change mRNA properties and function to get a comprehensive picture of the structure–activity relationship, modified 5' cap analogues are not commercially available and their synthesis and purification requires technical expertise and equipment beyond routine.

In particular, the site-specific methylation of guanosine at the 5' cap at a late stage of chemical synthesis can pose problems.⁹ Enzymatic methylation of 5' caps or short synthetic RNAs with a 5' cap at the late stage of chemical synthesis has

^aUniversity of Münster, Department of Chemistry, Institute of Biochemistry, Corrensstr. 36, 48149 Münster, Germany. E-mail: a.rentmeister@uni-muenster.de

^bUniversity of Münster, Cells in Motion Interfaculty Centre, Waldeyerstr. 15, 48149, Münster, Germany

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3sc03822j>

‡ These authors contributed equally.



MAT/MTase cascade:




Fig. 1 Cascade reactions for methylation in nature and application for site-specific alkylation and benzylation. (A) Methionine and ATP are reacted by methionine adenosyltransferase (MAT) to form the cofactor *S*-adenosyl-L-methionine (AdoMet or SAM). AdoMet can be used by methyltransferases (MTases) for the stereo-, regio- and chemo-selective methylation of DNA, RNA, proteins and small molecules. (B) Synthetic methionine analogues are used in MAT/MTase cascade reactions to transfer non-natural alkyl moieties to biomolecules.¹² (C) Photocleavable groups derived from the 2-nitrobenzyl group can be transferred by an engineered MAT/MTase cascade to photocage DNA.¹⁴ (D) This work shows that MAT/MTase cascades are a general tool to transfer (hetero)-benzylic moieties and can be used to modify mRNA at the 5' cap.

repeatedly been used to solve this issue.¹⁰ We propose the enzymatic late-stage modification of commercially available 5' caps or mRNAs with unmodified cap precursors (*i.e.* GpppG or GpppA) as an attractive alternative. The post-synthetic modification of mRNAs with a symmetric GpppG at the 5' end solves the problem of statistical wrong cap incorporation encountered in co-transcriptional capping using modified 5' caps.^{8a,11}

Most natural modifications at the 5' cap are methyl groups installed by methyltransferases (MTases) using the cosubstrate *S*-adenosyl-L-methionine (AdoMet or SAM). Previous work by several groups, including ours, demonstrated the use of various MTases in combination with AdoMet analogues to modify DNA, RNA, proteins and small molecules with various groups in a regio- and chemo-selective manner (Fig. 1).¹² With respect to the 5' cap, we reported on MTase-based modification of the N7G, N²G and N⁶A of m⁷GpppAm with the help of AdoMet analogues.^{7a,b,13}

However, these AdoMet analogues show limited half-lives in aqueous solution and their synthesis, although simple, is low yielding.¹⁵ Shipping the compounds can lead to partial degradation, limiting the exchange of materials and collaborations. Therefore, the enzymatic *in situ* generation of AdoMet analogues for direct use by MTases in cascade reactions presents an attractive alternative. Methionine adenosyltransferases (MATs) catalyse AdoMet formation from methionine and ATP.¹⁶ Starting from synthetic methionine analogues (Fig. 1B) a MAT/MTase cascade has been used *in vitro* for the late-stage alkyl-randomization of natural products, such as rebeccamycin^{12b} or rapamycin analogues.¹⁷ We reported MAT/MTase cascades for the modification of the 5' cap with allyl and propargyl residues,¹⁸ but did not find activity with benzylic groups^{18a} due to limited substrate promiscuity of the MAT. Thorson and coworkers systematically studied methionine analogues with

several wild type MAT enzymes, but benzylation remained elusive due to the low promiscuity of most MATs.^{12b}

Site-directed mutagenesis yielded MAT variants improved on methionine analogues with alkyl groups.^{12c,19} We then engineered a MAT variant from *Methanocaldococcus jannaschii* (MjMAT L147A/I351), termed PC-MjMAT, with high activity on 2-nitrobenzyl-containing methionine analogues (Fig. 1C), and solved the crystal structures in complex with an *ortho*-nitrobenzyl (ONB)-containing AdoMet analogue (AdoONB) and derivatives.^{14,20}

The results from MAT engineering and crystal structure analysis led us to hypothesize that the binding pocket is not specific for AdoONB and PC-MjMAT might accommodate a variety of benzylic AdoMet analogues in a similar binding mode, involving π -stacking of the benzyl ring and the adenine moiety of such analogues (Fig. 1D). As MTases can be highly promiscuous, the enzymatic generation of benzylic AdoMet analogues could substantially broaden the scope of enzymatic alkyl randomization to benzyl randomization of biomolecules and 5' cap modifications starting from simple amino acids.

Results and discussion

Enzymatic generation of AdoMet analogues with benzylic moieties

First, *D,L*-methionine analogues (1b–g, Fig. 2A) with benzylic side chains were synthesized in one-pot reactions from cheap *D,L*-homocysteine thiolactone (HCTL), purified by preparative HPLC (Fig. S1†) and analysed by LC-QTOF-MS (Fig. S2 and S3†) and ¹H-, ¹³C- or ¹⁹F-NMR (Fig. S4–S16†). The benzylic substituents all represent electron-poor aromatic systems, which we assumed to speed up the methyltransferase reaction based on



the Hammett equation. Methionine analogues **1e** and **1f** have been previously synthesized by us and others and could not be converted by any MAT variant tested so far,^{12b,18a} while the syntheses of **1b**, **1c**, **1d** and **1g** are reported for the first time to the best of our knowledge.

We tested the activity of PC-MjMAT on methionine (**1a**) and these benzylic methionine analogues (**1b–g**). At 37 °C the AdoMet and AdoMet analogues (**2a–g**) can be detected in the reaction mixture. At 65 °C, however, they are degraded to stable

methylthioadenosine (MTA) analogues (**3a–g**) (Fig. 2 and S17†). The reaction at 65 °C, leading to MTA formation, thus provides a fast and direct assay to measure MAT activity without product inhibition. To our delight, the HPLC analysis showed that PC-MjMAT is active on all methionine analogues **1b–g**, as the respective AdoMet analogues (**2b–g**) and MTA analogues (**3a–g**) are formed (Fig. 2B–G and S17†). Formation of AdoMet analogues **2b–g** was validated by LC-QTOF-MS (Fig. S18–S23†). The reactions without amino acid did not show a new peak and served as negative control (Fig. S17†). These data show that a broad range of benzylic methionine analogues are readily converted by PC-MjMAT at different temperatures.

MAT/MTase cascades for versatile site-specific benzylation of complex small molecules

To test whether the generated AdoMet analogues can serve as MTase co-substrates *in situ*, we first used NovO, a coumarin




Fig. 2 MAT reaction with methionine and benzylic methionine analogues. (A) Reaction scheme with methionine **1a** and benzylic methionine analogues (**1b–g**) prepared for this study. The AdoMet analogues (**2b–g**) and heat-induced degradation products (MTA analogues, **3a–g**) are monitored to circumvent effects from product inhibition. PC-MjMAT is an engineered MAT variant from *Methanocaldococcus jannaschii* (MjMAT L147A/I351A). (B–G) HPLC analyses of reactions with the indicated amino acid performed at 37 °C or 65 °C. Conditions: 5 mM **1b–g**, 5 mM ATP, 100 μ M PC-MjMAT at 37 °C or 65 °C for 1 h in a total volume of 30 μ L. Reaction buffer (1 \times) consisted of 50 mM HEPES, 10 mM MgCl₂, 5 mM KCl (pH = 7.4). Adenosine (A) results from background deupuration.




Fig. 3 Substrate scope of enzymatic benzylation of small molecules in two MAT/MTase cascade reactions. (A) The PC-MjMAT/NovO cascade converts 4,5,7-trihydroxy-3-phenylcoumarin (**4**) to derivatives **4a–g**, benzylation at the C8-position. (B) Representative HPLC analyses of the cascade reactions of **4** with **1a–g**. (C) Evaluation of conversions from **4** to **4a–g** calculated from the peak area ($n = 3$). Conditions: 5 mM **1a–g**, 5 mM ATP, 100 μ M PC-MjMAT, 50 μ M NovO, 10 μ M MTAN, 1 mM **4** at 37 °C for 2 h. (D) The PC-MjMAT/Ecm1 cascade converts the dinucleotide GpppA (**5**) to derivatives **5a–g**, benzylation at the N7-position of guanosine. (E) Representative HPLC analyses of the cascade reactions of **5** with **1a–g**. (F) Evaluation of conversions from **5** to **5a–g** calculated from peak area ($n = 3$). Conditions: 5 mM **1a–g**, 5 mM ATP, 100 μ M PC-MjMAT, 50 μ M Ecm1, 10 μ M MTAN, 500 μ M **5** at 37 °C for 2 h.



MTase from *Streptomyces niveus* involved in the biosynthesis of the aminocoumarin antibiotic novobiocin (Fig. 3A).²¹ NovO selectively modifies the C8-position of a range of 7-hydroxycoumarine derivatives and was previously shown to accept bulky AdoMet analogues.²² We tested methionine (**1a**) and analogues **1b–g** in the PC-MjMAT/NovO cascade using 3,4,7-trihydroxy-3-phenyl-coumarin (THPC, **4**) as substrate and monitored the conversion *via* HPLC at 320 nm (Fig. 3B, S24 and S25†). To our delight, **1a–e** resulted in almost quantitative conversions to 100% **4a**, 98% **4b**, 99% **4c**, 95% **4d**, and 100% **4e**, respectively. Analogue **1f** gave satisfactory conversion (72% **4f**), whereas conversion of **1g** was low (8% **4g**) (Fig. 3C). Products **4a–g** were confirmed by LC-QTOF-MS (Fig. S26–S32†).

N7G-modified GpppA

Next, we turned our attention to the dinucleotide GpppA (**5**), which forms the 5' cap of mRNA and can be used for the production of capped mRNA by *in vitro* transcription (IVT).²³ We established a cascade of PC-MjMAT with Ecm1, the mRNA cap (guanine N7) methyltransferase from *Encephalitozoon cuniculi*,²⁴ and monitored the N7G modification of **5** by HPLC (Fig. 3D and E, S33 and S34†). Using **1a–f**, conversions were almost complete (>99% **5a–f**). Using **1g**, the conversion still reached 70%. Products **5a–g** were confirmed by LC-QTOF-MS (Fig. S35–S41†). These results show that PC-MjMAT displays remarkable promiscuity for benzylic groups and compatibility with at least two different MTases.

Evaluation of N7G-modified-mRNAs starting with GpppA

To test how modifications at the N7G of the 5' cap affect protein production, we modified GpppA *via* PC-MjMAT/Ecm1 cascade reactions and purified **5b–d** by HPLC to then use them for co-transcriptional capping of *Gaussia luciferase* (GLuc) mRNA. To ensure that exclusively capped mRNA is assessed in subsequent experiments, uncapped RNA was routinely digested by polyphosphatase and XRN1. Translation assays showed that **5b–d** caps result in 40%, 22%, and 11% GLuc activity, respectively, compared to ARCA-GLuc in HeLa cells (Fig. S42A†). Due to this low amount of protein produced from **5b–d** capped mRNAs in HeLa cells, we compared ARCA-, m⁷GpppA- and m⁷GpppG-capped mRNA in RRL and HeLa cells (Fig. S42B†). While m⁷GpppA- and m⁷GpppG-capped mRNAs performed similarly *in vitro*, protein production in HeLa cells was higher for m⁷GpppG-capped mRNA. We therefore switched to GpppG-based 5' cap analogues from which higher amounts of protein are produced.

N7-modified GpppG

The PC-MjMAT/Ecm1 cascade with **1b–d** was thus applied to GpppG (**6**). This can lead to N7G modification at one (**6b–d**) or both Gs. After optimization, we were able to convert GpppG (**6**) to **6b–d** in good yields without formation of the double modified products (Fig. 4A, B and S43†). The products **6b–d** were purified *via* semi-preparative HPLC and the identity was confirmed by LC-QTOF-MS (Fig. S44–S50†). Before using the isolated 5' caps **6b–d** as LC-QqQ-MS standards for quantification and analysis




Fig. 4 Enzymatic generation of N7-modified GpppG caps and analysis of post-transcriptionally modified GpppG-RNAs. (A) Structure of N7-modified GpppG caps (**6b–d**). (B) Conversion of GpppG to **6b–d** calculated from the HPLC peak area ($n = 3$). Conditions: 5 mM **1b/c** or 8 mM **1d**, 5 mM ATP, 100 μ M PC-MjMAT, 50 μ M Ecm1, 10 μ M MTAN, 2 mM **6** at 37 °C for 2 h. (C) Determination of the concentration of purified 5' caps **6b–d**. **6b–d** were digested into nucleosides using snake venom phosphodiesterase (PDE), dephosphorylated using FastAP and quantified by HPLC using an external standard. (D) Scheme illustrating post-synthetic modification to obtain mRNAs with different 5' cap modifications. GpppG-mRNAs are modified *via* the enzymatic PC-MjMAT/Ecm1 cascade. Nuclease P1 digests the mRNA while leaving the 5' caps (**6**, **6a–d**) intact for LC-QqQ analysis. (E) Analysis of mRNA integrity after the PC-MjMAT/Ecm1 cascade. M: marker, control: GpppG-RNA, **6**-RNA: GpppG-RNA incubated in PC-MjMAT/Ecm1 reaction mixture without enzymes. Reaction conditions: 0.2 μ M mRNA, 2.5 μ M PC-MjMAT, 2.5 μ M MTAN, 50 μ M **1a–d**, 50 μ M ATP, 1 μ M Ecm1 in 0.5 \times NEB CutSmart buffer at 37 °C for 3 h. (F) Conversion of post-synthetic 5' cap modification of GpppG-mRNA *via* the chemo-enzymatic cascade. Results show LC-QqQ-MS analysis, as illustrated in (D).

of the chemo-enzymatic modification of mRNAs, we needed to determine their exact concentrations. To achieve this, we digested **6b–d** with snake venom phosphodiesterase (PDE) and



quantified the resulting guanosine (7) peak by HPLC (Fig. 4C and S51A†). This enzymatic approach provides rapid access to synthetic standards of modified 5' cap analogues, which are required for quantification but not commercially available and tedious to synthesize by chemical means alone.

Post-synthetic modification of mRNA and analysis

With LC-MS-based methodology to quantify modified 5' caps from mRNA at hand, we converted GpppG-capped GLuc-mRNA *via* the PC-MjMAT/Ecm1 cascade (Fig. 4D). The approach relies on addition of symmetric GpppG during IVT and benefits from the site-specific post-transcriptional modification at the N7 position of the 5' terminal G. It elegantly circumvents wrong cap incorporation (where the N7-modified G is not the terminal nucleotide) as either orientation of GpppG yields identically capped mRNA, and once in mRNA only the terminal G is recognized by the enzyme Ecm1.

To ensure the quality of mRNA, we routinely removed uncapped RNA and tested the integrity of mRNA before biological assays (Fig. 4E). After optimization, we achieved quantitative modification of GpppG-capped-mRNA using **1a-d** without affecting RNA integrity. The conversion of mRNA modification at the 5' cap was determined for each mRNA sample, using the LC-QqQ method and synthetic standards (Fig. 4F). To this end, we digested mRNA with nuclease P1 into nucleosides and the intact cap. LC-QqQ-MS was then used to quantify modified and non-modified caps *via* external calibration, using optimized multiple reaction monitoring (MRM) settings for each fragment (Fig. S51B and C†).

Evaluation of the effect of N7G-modified-mRNAs starting with GpppG on the amount of protein produced

With these high-quality mRNA samples, we sought to investigate the effect of non-natural 5' cap modifications on protein production. We prepared *Renilla luciferase* (RLuc) reporter mRNAs with different 5' cap modifications. To ensure that we are looking at the effect of 5' cap modifications and rule out effects by the mRNA preparation, we prepared the mRNAs by two different procedures (Fig. 5): in the co-transcriptional approach, the N7-modified GpppG caps are added to the IVT mix (Fig. 5A and C) whereas in the post-transcriptional approach, the cascade reaction is performed on complete GpppG-capped mRNAs (Fig. 5B and D).

Both approaches yielded good amounts of intact mRNA (Fig. 4E and S52†). The amount of protein produced from differently prepared and cap-modified mRNAs was first tested in rabbit reticulocyte lysate (RRL), a eukaryotic cell-free expression system (Fig. 5A and B). The signals of luminescence were measured after 90 minutes of *in vitro* translation, and normalized to RLuc-mRNA capped with ARCA. N7G-modified caps used for co-transcriptional modification in IVT can be incorporated in different orientations and resulted in ~50% luciferase activity for m⁷GpppG (**6a**) compared to ARCA (Fig. 5A), in line with previous reports.^{8a,b,25} RLuc-mRNA with benzylic modifications, *i.e.* 5' caps **6b-d**, resulted in 65%, 46% and 34% luciferase activity respectively (Fig. 5A).




Fig. 5 Effect of mRNA 5' cap methylation and benzylation on the amount of protein produced *in vitro* and in cells. Co- and post-transcriptional 5' cap modification strategies were evaluated in parallel. (A and C) Luciferase activity from differently capped RLuc-mRNAs prepared *via in vitro* transcription (IVT) and translated in rabbit reticulocyte lysate (RRL) *in vitro* (A) or in HeLa cells (C). (B and D) Same assays, but with RLuc-mRNAs modified post-transcriptionally *via* the PC-MjMAT/Ecm1 cascade. The results are normalized to ARCA-RLuc-mRNA. The average value \pm SD of $n = 3$ independent experiments is shown. Statistical analysis: unpaired t-test. $p < 0.05$: *, $p < 0.01$: **, $p < 0.001$: ***, n.s.: not significant.

Performing the cascade on GpppG-capped RLuc circumvents the problem of wrong cap incorporation, as Ecm1 selectively modifies the terminal guanosine.²⁶ Post-transcriptional modification of GpppG-mRNA *via* the cascade starting from **1a-d** resulted in relative luciferase activities of 102%, 139%, 89% and 50%, respectively, *in vitro* (Fig. 5B). The commonly used ARCA cap was outperformed by the N7-(4-chlorobenzyl) modification installed in the cascade reaction (Fig. 5B).

To independently assess the effect of 5' cap modifications in cells, we transfected HeLa cells with the differently modified



RLuc-mRNAs and assayed 24 h after transfection (Fig. 5C and D). Again, both the co- and post-transcriptional methods were used for preparation. Compared to ARCA, co-transcriptionally modified mRNAs prepared by IVT gave luciferase activity of 55%, 79%, 43% and 27% for **6a–d** (Fig. 5C). Again, the post-transcriptionally modified mRNAs showed higher luciferase activity (Fig. 5D). With the cascade starting from **1a–d**, 93%, 128%, 70% and 43% luciferase activity relative to ARCA-capped mRNA were determined (Fig. 5D).

The direct comparison shows that the relative performance of all differently capped mRNAs is essentially the same *in vitro* and in cells (Fig. 5A vs. 5C and 5B vs. 5D). It is thus unlikely that other factors, such as different mRNA levels in cells, are the reason for the effects observed.

The comparison of co-transcriptionally and post-transcriptionally modified mRNAs (Fig. 5A to B and C to D) shows that mRNAs with 5' caps **6a–d** generated *via* the enzymatic cascade produce 148–200% protein, compared to ARCA-mRNAs, which cannot be incorporated in the wrong orientation and are not affected.

Analysis of 5' cap orientation and eIF4E binding

The amount of protein produced from different 5' cap modified mRNAs is the most relevant readout. It results, however, from several contributing factors, which can have convoluted and even contradicting effects. We aimed to further dissect the positive effect of post-transcriptional modification by determining the contribution of correct cap incorporation. To this end, we produced short mRNAs (24-mers) with different 5' caps by IVT in the presence of **6a–d**. The integrity of the 24-mer mRNAs was confirmed by gel electrophoresis (Fig. 6E).

To analyse the orientation of the 5' cap, *i.e.* whether the N7-modified G is terminal or at the TSN, we capitalized on the site-

specificity of the 5' cap methyltransferase *GlaTgs2*, which can only methylate terminal m⁷G but not terminal G or internal m⁷G.^{13a,24,27} We incubated the mRNAs with *GlaTgs2* and SAM. This leads to additional complete N² methylation only in the case of correct 5' cap orientation (Fig. 6A), even when the N7G is modified with non-natural groups.^{18b} After digestion into 5' cap and nucleosides, the fraction of correct orientation can then be determined from the ratio of methylated and unmethylated product by HPLC analysis (Fig. 6B, C and S53†). For mRNAs with 5' caps **6a–d**, we found 61%, 79%, 80% and 88% of them in the correct orientation, respectively (Fig. 6D). These data indicate that bulkier N7-modifications improve correct 5' cap incorporation during IVT. The effect can be rationalized by the bulkiness of the modifications and a stronger effect on the G that serves as TSN than the terminal G, which is *per se* already an extension. The result suggests that 5' caps with bulky N7G modifications also alleviate the problem of wrong cap incorporation in a co-transcriptional approach. However, our data for wrong cap incorporation of **6b–d** cannot explain the trend for protein production observed in RRL and in cells.

Another factor contributing to improved translational output of mRNAs could be higher affinity to the translation initiation factor eIF4E.^{7c,28} To test the effect of benzylic 5' cap modifications on binding to eIF4E, we performed binding assays of **6a–d** with fluorescently labelled eIF4E, using microscale thermophoresis (MST). ARCA and **6a** showed the highest affinities with *K_d* values in the low μM range. All N7-benzylated 5' caps bound less tightly (Fig. S54†). Based on this data, the affinity to eIF4E is not responsible for the observed increase in protein production.

Evaluation of the effect of N7G-modified-mRNAs starting with GpppG on the immune response in HEK-NF-κB cell lines

Next, we sought to evaluate the effects of the non-natural modifications on the immune response. To study if 5' cap modifications affect the activation of pathogen recognition receptors (PRRs), we used four HEK-NF-κB cell lines (Null, TLR3, TLR7, TLR8). All these cell lines express the firefly luciferase gene driven by the NF-κB response element after activation of PRRs such as RIG-I, MDA5, and PKR (Fig. 7A). Additionally, HEK-NF-κB-TLR3, HEK-NF-κB-TLR7 and HEK-NF-κB-TLR8 overexpress the respective Toll-like receptor (TLR). TLRs recognize foreign RNAs and initiate another signalling pathway triggering expression of genes driven by the NF-κB response element (Fig. 7A). Transfection of different HEK-NF-κB cell lines with GpppG-RLuc-mRNA that was modified either co- or post-transcriptionally *via* PC-MjMAT/Ecm1 revealed that 5' cap modifications can, in some cases, alter the immunogenicity of RNA compared to control RNA (m⁷GpppG-RLuc) that was used as a reference (Fig. 7B–E). The overall effect on NF-κB activation from co- and post-transcriptionally modified mRNAs was similar for all tested HEK-NF-κB cell lines. While ARCA-mRNA and **6b**-mRNA led to similar levels of activation of the NF-κB pathway in HEK-NF-κB-TLR Null, TLR3 and TLR8 cells, we found significantly lower activation by **6b**-mRNA in TLR 7 cells.

In parallel, we measured protein production *via* a luminescence assay in HEK-NF-κB cell lines (Fig. 7F–I). The protein




Fig. 6 (A) Scheme of HPLC-based 5' cap orientation assay. m²**6a–d** (terminal = correct orientation), **6a–d** (internal = wrong orientation). (B and C) Representative HPLC analysis of the 5' cap incorporation assay in co-transcriptionally modified RNA using **6a–b**, respectively. (D) Evaluation of 5' cap orientation assay for mRNAs with **6a–d** (*n* = 3). (E) Integrity of RNA 24mer used in 5' cap orientation assay, analysed by PAA gel (15% TBE).






Fig. 7 Effect of mRNA 5' cap methylation and benzylation on the immune response and protein production in HEK-NF- κ B reporter cell lines. Co- and post-transcriptional 5' cap modification strategies were evaluated in parallel. (A) Concept of activation of pathogen recognition receptors such as PKR, MDA5, and RIG-I in the HEK-NF- κ B null cell line triggering Firefly luciferase (FLuc) expression. Created with <http://BioRender.com>. (B–E) Indicated HEK-NF- κ B cells (Null, TLR3, TLR7, TLR8) were transfected with differently capped RLuc-mRNAs and NF- κ B activation was quantified *via* FLuc activity. Data are normalized to the ARCA-mRNA. (F–I) RLuc activity as a measure of protein production in indicated HEK-NF- κ B cells transfected with differently capped RLuc-mRNAs. Data of $n = 3$ independent experiments are shown as average values \pm SD. Statistical analysis: unpaired t -test. $p < 0.05$: *, $p < 0.01$: **, $p < 0.001$: ***, n.s.: not significant.

production for different mRNA 5' cap modifications showed the same trend as the data in HeLa cells (Fig. 5C and D). Of note, we observed for **6b**-mRNAs made by the post-synthetic approach that even more protein is produced compared to ARCA-mRNAs, specifically, HEK-NF- κ B for the null (139%), TLR3 (146%), TLR7 (150%), and TLR8 (143%) cell lines, respectively (Fig. 7F–I). As higher activation of the immune response has a negative impact on translation, our data suggest that lower activation of TLR7 might play a role in the observed effects of **6b**-mRNA on protein output.

Conclusions

This work presents a convenient and robust method for the regioselective modification of small molecules and mRNAs, which can likely be readily extended to other methyltransferase targets. Stable D,L -methionine analogues can be accessed in one pot in up to half-gram scale starting from cheap homocysteine thiolactone (HCTL). The engineered MAT (PC-MjMAT) efficiently generates the corresponding AdoMet analogues that are substrates for promiscuous methyltransferases, as shown here for NovO and Ecm1. The post-transcriptional modification *via* the PC-MjMAT/Ecm1 cascade ensures specificity for the terminal G when applied to full-length GpppG-capped mRNAs. When N7-modified 5' caps are added co-transcriptionally to the IVT, however, they can be incorporated in different orientations.

We found in several different systems consistently that mRNAs post-transcriptionally modified with an N7-(4-chlorobenzyl) group (**6b**-mRNAs) led to more protein output than the widely used ARCA-mRNAs. This was true *in vitro* (139%), in HeLa cells (128%) and in four different HEK cell lines (139–150%).

The effect of this 5' cap modification could not be pinpointed to a single contributing factor; however, a number of factors, such as differences in transfection, better incorporation in IVT or binding to eIF4E could be ruled out. Our data suggest a role in lower activation of TLR7, however studies with primary cells will be required for validation. The low activation of cytosolic PRRs, in particular of TLR7, by **6b**-mRNAs suggests that benzylic 5' cap modifications can be a useful approach contributing to future mRNA therapy.

Data availability

All data are available in the ESI.†

Author contributions

N. V. C. and A. R. conceived the project. N. V. C., R. M., M. E., N. M., A. P. and A. B. designed and performed experiments. All authors discussed the results. N. V. C., R. M. and A. R. wrote the paper.

Conflicts of interest

There are no conflicts to declare.



Acknowledgements

A. R. thanks the DFG (CRC 1459 Project ID 433682494, IRTG2678) for financial support. R. M. was supported by a fellowship from the CRC 1459. We thank Ann-Marie Lawrence-Dörner and Dr Wolfgang Dörner for excellent technical assistance, Sabine Hüwel for culturing HeLa cells, Dr Petr Špaček for assistance with LC-QqQ-MS measurements, and Melissa van Dülmen for discussions. The mass spectrometry and NMR facilities of the organic chemistry department are gratefully acknowledged for analytical services. We thank TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz) for providing us with the HEK-NF- κ B cell lines.

References

- 1 L. A. Jackson, E. J. Anderson, N. G. Roupheal, P. C. Roberts, M. Makhene, R. N. Coler, M. P. McCullough, J. D. Chappell, M. R. Denison, L. J. Stevens, A. J. Pruijssers, A. McDermott, B. Flach, N. A. Doria-Rose, K. S. Corbett, K. M. Morabito, S. O'Dell, S. D. Schmidt, P. A. Swanson 2nd, M. Padilla, J. R. Mascola, K. M. Neuzil, H. Bennett, W. Sun, E. Peters, M. Makowski, J. Albert, K. Cross, W. Buchanan, R. Pikaart-Tautges, J. E. Ledgerwood, B. S. Graham and J. H. Beigel, *N. Engl. J. Med.*, 2020, **383**, 1920–1931.
- 2 C. L. Lorentzen, J. B. Haanen, Ö. Met and I. M. Svane, *Lancet Oncol.*, 2022, **23**, e450–e458.
- 3 (a) S. Ramaswamy, N. Tonnu, K. Tachikawa, P. Limphong, J. B. Vega, P. P. Karmali, P. Chivukula and I. M. Verma, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E1941–e1950; (b) C. G. Perez-Garcia, R. Diaz-Trelles, J. B. Vega, Y. Bao, M. Sablad, P. Limphong, S. Chikamatsu, H. Yu, W. Taylor, P. P. Karmali, K. Tachikawa and P. Chivukula, *Mol. Ther. – Nucleic Acids*, 2022, **28**, 87–98.
- 4 E. Rohner, R. Yang, K. S. Foo, A. Goedel and K. R. Chien, *Nat. Biotechnol.*, 2022, **40**, 1586–1600.
- 5 (a) D. Strzelecka, M. Smietanski, P. J. Sikorski, M. Warminski, J. Kowalska and J. Jemielity, *RNA*, 2020, **26**, 1815–1837; (b) B. A. Wojtczak, P. J. Sikorski, K. Fac-Dabrowska, A. Nowicka, M. Warminski, D. Kubacka, E. Nowak, M. Nowotny, J. Kowalska and J. Jemielity, *J. Am. Chem. Soc.*, 2018, **140**, 5987–5999; (c) K. Drazkowska, R. Tomecki, M. Warminski, N. Baran, D. Cysewski, A. Depaix, R. Kasprzyk, J. Kowalska, J. Jemielity and P. J. Sikorski, *Nucleic Acids Res.*, 2022, **50**, 9051–9071.
- 6 N. Sonenberg and A. C. Gingras, *Curr. Opin. Cell Biol.*, 1998, **10**, 268–275.
- 7 (a) J. M. Holstein, L. Anhauser and A. Rentmeister, *Angew. Chem., Int. Ed.*, 2016, **55**, 10899–10903; (b) M. van Dülmen, N. Muthmann and A. Rentmeister, *Angew. Chem., Int. Ed.*, 2021, **60**, 13280–13286; (c) N. Klöcker, F. P. Weissenboeck, M. van Dülmen, P. Spacek, S. Hüwel and A. Rentmeister, *Nat. Chem.*, 2022, **14**, 905–913; (d) P. J. Sikorski, M. Warminski, D. Kubacka, T. Ratajczak, D. Nowis, J. Kowalska and J. Jemielity, *Nucleic Acids Res.*, 2020, **48**, 1607–1626; (e) M. Warminski, J. Kowalska, E. Nowak, D. Kubacka, R. Tibble, R. Kasprzyk, P. J. Sikorski, J. D. Gross, M. Nowotny and J. Jemielity, *ACS Chem. Biol.*, 2021, **16**, 334–343.
- 8 (a) J. Stepinski, C. Waddell, R. Stolarski, E. Darzynkiewicz and R. E. Rhoads, *Rna*, 2001, **7**, 1486–1495; (b) J. Jemielity, T. Fowler, J. Zuberek, J. Stepinski, M. Lewdorowicz, A. Niedzwiecka, R. Stolarski, E. Darzynkiewicz and R. E. Rhoads, *Rna*, 2003, **9**, 1108–1122; (c) F. Muttach, N. Muthmann and A. Rentmeister, *Org. Biomol. Chem.*, 2017, **15**, 278–284.
- 9 J. Jemielity, R. Stolarski and E. Darzynkiewicz, *Nucleosides, Nucleotides Nucleic Acids*, 2007, **26**, 1315–1319.
- 10 (a) N. Muthmann, T. Guez, J. J. Vasseur, S. R. Jaffrey, F. Debart and A. Rentmeister, *ChemBioChem*, 2019, **20**, 1693–1700; (b) J. Leiter, D. Reichert, A. Rentmeister and R. Micura, *ChemBioChem*, 2020, **21**, 265–271; (c) A. Shannon, B. Sama, P. Gauffre, T. Guez, F. Debart, J. J. Vasseur, E. Decroly, B. Canard and F. Ferron, *Nucleic Acids Res.*, 2022, **50**, 11186–11198.
- 11 A. E. Pasquinelli, J. E. Dahlberg and E. Lund, *RNA*, 1995, **1**, 957–967.
- 12 (a) F. Muttach and A. Rentmeister, *Methods*, 2016, **107**, 3–9; (b) S. Singh, J. Zhang, T. D. Huber, M. Sunkara, K. Hurley, R. D. Goff, G. Wang, W. Zhang, C. Liu, J. Rohr, S. G. Van Lanen, A. J. Morris and J. S. Thorson, *Angew. Chem., Int. Ed.*, 2014, **53**, 3965–3969; (c) R. Wang, K. Islam, Y. Liu, W. Zheng, H. Tang, N. Lailler, G. Blum, H. Deng and M. Luo, *J. Am. Chem. Soc.*, 2013, **135**, 1048–1056; (d) K. Islam, I. Bothwell, Y. Chen, C. Sengelaub, R. Wang, H. Deng and M. Luo, *J. Am. Chem. Soc.*, 2012, **134**, 5909–5915.
- 13 (a) D. Schulz, J. M. Holstein and A. Rentmeister, *Angew. Chem., Int. Ed.*, 2013, **52**, 7874–7878; (b) J. M. Holstein, D. Schulz and A. Rentmeister, *Chem. Commun.*, 2014, **50**, 4478–4481; (c) J. M. Holstein, D. Stummer and A. Rentmeister, *Chem. Sci.*, 2015, **6**, 1362–1369; (d) A. Ovcharenko, F. P. Weissenboeck and A. Rentmeister, *Angew. Chem., Int. Ed.*, 2020, **60**, 4098; (e) N. Klöcker, L. Anhäuser and A. Rentmeister, *ChemBioChem*, 2022, e202200522; (f) A. Bollu, A. Peters and A. Rentmeister, *Acc. Chem. Res.*, 2022, **55**, 1249–1261.
- 14 (a) F. Michailidou, N. Klöcker, N. V. Cornelissen, R. K. Singh, A. Peters, A. Ovcharenko, D. Kümmel and A. Rentmeister, *Angew. Chem., Int. Ed.*, 2021, **60**, 480–485; (b) A. Peters, E. Herrmann, N. V. Cornelissen, N. Klöcker, D. Kümmel and A. Rentmeister, *ChemBioChem*, 2022, **23**, e202100437.
- 15 G. Lukinavicius, V. Lapiene, Z. Stasevskij, C. Dalhoff, E. Weinhold and S. Klimauskas, *J. Am. Chem. Soc.*, 2007, **129**, 2758–2759.
- 16 (a) J. L. Hoffman, *Biochemistry*, 1986, **25**, 4444–4449; (b) G. de la Haba, G. A. Jamieson, S. H. Mudd and H. H. Richards, *J. Am. Chem. Soc.*, 1959, **81**, 3975–3980; (c) Z. J. Lu and G. D. Markham, *J. Biol. Chem.*, 2002, **277**, 16624–16631; (d) R. S. Firestone and V. L. Schramm, *J. Am. Chem. Soc.*, 2017, **139**, 13754–13760.
- 17 B. J. C. Law, A. W. Struck, M. R. Bennett, B. Wilkinson and J. Micklefield, *Chem. Sci.*, 2015, **6**, 2885–2892.



- 18 (a) F. Muttach and A. Rentmeister, *Angew. Chem., Int. Ed.*, 2016, **55**, 1917–1920; (b) J. M. Holstein, F. Muttach, S. H. H. Schiefelbein and A. Rentmeister, *Chemistry*, 2017, **23**, 6165–6173.
- 19 M. Dippe, W. Brandt, H. Rost, A. Porzel, J. Schmidt and L. A. Wessjohann, *Chem. Commun.*, 2015, **51**, 3637–3640.
- 20 M. Erguven, N. V. Cornelissen, A. Peters, E. Karaca and A. Rentmeister, *ChemBioChem*, 2022, **23**, e202200511.
- 21 M. Pacholec, J. Tao and C. T. Walsh, *Biochemistry*, 2005, **44**, 14969–14976.
- 22 (a) H. Stecher, M. Tengg, B. J. Ueberbacher, P. Remler, H. Schwab, H. Griengl and M. Gruber-Khadjawi, *Angew. Chem., Int. Ed.*, 2009, **48**, 9546–9548; (b) J. C. Sadler, C.-w. H. Chung, J. E. Mosley, G. A. Burley and L. D. Humphreys, *ACS Chem. Biol.*, 2017, **12**, 374–379; (c) I. J. W. McKean, J. C. Sadler, A. Cuetos, A. Frese, L. D. Humphreys, G. Grogan, P. A. Hoskisson and G. A. Burley, *Angew. Chem., Int. Ed.*, 2019, **58**, 17583–17588.
- 23 T. M. Coleman, G. Wang and F. Huang, *Nucleic Acids Res.*, 2004, **32**, e14.
- 24 S. Hausmann, S. Zheng, C. Fabrega, S. W. Schneller, C. D. Lima and S. Shuman, *J. Biol. Chem.*, 2005, **280**, 20404–20412.
- 25 I. Kocmik, K. Piecyk, M. Rudzinska, A. Niedzwiecka, E. Darzynkiewicz, R. Grzela and M. Jankowska-Anyszka, *Cell Cycle*, 2018, **17**, 1624–1636.
- 26 N. Muthmann, P. Spacek, D. Reichert, M. van Dülmen and A. Rentmeister, *Methods*, 2021, **203**, 196–206.
- 27 S. Hausmann, C. P. Vivares and S. Shuman, *J. Biol. Chem.*, 2002, **277**, 96–103.
- 28 (a) A. R. Kore, Z. Xiao and M. Li, *Bioorg. Med. Chem.*, 2013, **21**, 4570–4574; (b) R. Wojcik, M. R. Baranowski, L. Markiewicz, D. Kubacka, M. Bednarczyk, N. Baran, A. Wojtczak, P. J. Sikorski, J. Zuberek, J. Kowalska and J. Jemielity, *Pharmaceutics*, 2021, **13**; (c) A. Niedzwiecka, J. Marcotrigiano, J. Stepinski, M. Jankowska-Anyszka, A. Wyslouch-Cieszynska, M. Dadlez, A.-C. Gingras, P. Mak, E. Darzynkiewicz, N. Sonenberg, S. K. Burley and R. Stolarski, *J. Mol. Biol.*, 2002, **319**, 615–635; (d) D. Barnes-Seeman, S. L. Cohen, J. L. Diener, C. Gampe, J. Roache, A. White, S. L. Williams, J. Yuan and F. Zecri, in *3' end caps, 5' end caps and combinations thereof for therapeutic RNA*, Novartis AG, 2020.

